Catalyst is a biopharmaceutical company focused on the development and commercialization of prescription drugs to fight addictions, manage pain, and treat diseases of the central nervous system such as epilepsy.
Catalyst is developing vigabatrin (vi•gá•ba•trin, designated CPP-109 by Catalyst) for the treatment of addiction to cocaine, methamphetamine, and other addictive substances. Catalyst is also developing a more potent form of vigabatrin (designated CPP-115 by Catalyst) to combat drug addiction — including opiate addiction in managing pain — and to treat central nervous system indications such as epilepsy. catalystpharma.com |
